Endometrial Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateGynaecological CancersEndometrial CancerSCE Medical Oncology

A 60-year-old woman with advanced endometrial cancer (pMMR/MSS, p53 wild-type) has progressed on first-line carboplatin + paclitaxel. ECOG PS 1. What is the recommended second-line therapy?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Lenvatinib + pembrolizumab

The KEYNOTE-775/Study 309 trial demonstrated that lenvatinib + pembrolizumab significantly improved PFS and OS versus chemotherapy in advanced endometrial cancer after prior platinum therapy, regardless of MSI status (NICE TA902). The benefit was seen in both pMMR and dMMR populations, though the magnitude was greater in pMMR. This combination specifically addresses the pMMR/MSS subgroup where ICI monotherapy has limited activity.

Reference: NICE TA902 Lenvatinib + pembrolizumab for previously treated advanced endometrial cancer; KEYNOTE-775